Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty acyl-CoAs and insulin action in type 2 diabetic patients

Diabetes

Volumn 54, Issue 11, 2005, Pages 3148-3153

  Bajaj, Mandeep ^a,c   Suraamornkul, Swangjit ^a   Romanelli, Anthony ^b   Cline, Gary W ^b   Mandarino, Lawrence J ^a   Shulman, Gerald I ^b   DeFronzo, Ralph A ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIPIMOX; ADIPONECTIN; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LONG CHAIN FATTY ACID COENZYME A LIGASE; PALMITOYL COENZYME A;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FATTY ACID BLOOD LEVEL; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN SENSITIVITY; LIPOLYSIS; MALE; MUSCLE; MUSCLE BIOPSY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE; VASTUS LATERALIS MUSCLE;

ACYL COENZYME A; ADIPONECTIN; ANTILIPEMIC AGENTS; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERLIPIDEMIAS; INSULIN; MALE; MIDDLE AGED; MUSCLE, SKELETAL; PYRAZINES;

EID: 33644695097     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/diabetes.54.11.3148     Document Type: Article

References (53)

1. Bajaj M, Defronzo RA: Metabolic and molecular basis of insulin resistance. J Nucl Cardiol 10:311-323, 2003
2. Groop LC, Bonadonna RC, Del Prato S, Ratheiser K, Zyck K, DeFronzo RA: Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus: evidence for multiple sites of insulin resistance. J Clin Invest 84:205-213, 1989
3. Groop L, Saloranta C, Shank M, Bonadonna RC, Ferrannini E, DeFronzo RA: The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab 72:96-107, 1991
4. Reaven GM: The fourth Musketeer: from Alexandre Dumas to Claude Bernard. Diabetologia 38:3-13, 1995
5. Boden G, Jadali F, White J, Liang Y, Mozzoli M, Chen X, Coleman E, Smith C: Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest 88:960-966, 1991
6. Felber JP, Ferrannini E, Golay A, Meyer HV, Thiebaud D, Curchod B, Maeder E, Jequier E, DeFronzo RA: Role of lipid oxidation in the pathogenesis of insulin resistance of obesity and type II diabetes. Diabetes 36:1341-1350, 1987
7. Boden G, Chen X: Effect of fat on glucose uptake and utilization in patients with non-insulin dependent diabetes. J Clin Invest 96:1261-1268, 1995
8. Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10, 1997
9. Roden M, Krssak M, Stingl H, Gruber S, Hofer A, Furnsinn C, Moser E, Waldhausl W: Rapid impairment of skeletal muscle glucose transport/ phosphorylation by free fatty acids in humans. Diabetes 48:358-364, 1999
10. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, Shulman GI: Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 97:2859-2865, 1996
11. Randle PJ, Newsholme EA, Garland PB: Regulation of glucose uptake by muscle: effects of fatty acids, ketone bodies and pyruvate, and of alloxandiabetes and starvation on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem J 93:652-665, 1964
12. Chen X, Iqbal N, Boden G: The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J Clin Invest 103:365-372, 1999
13. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA: Effect of fatty acids on glucose production and utilization in man. J Clin Invest 72:1737-1747, 1983
14. Greco AV, Mingrone G, Giancaterini A, Manco M, Morroni M, Cinti S, Granzotto M, Vettor R, Camastra S, Ferrannini E: Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes 51:144-151, 2002
15. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA: Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52:1364-1370, 2003
16. Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 106:171-176, 2000
17. Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, Lutz EP, Kako Y, Velez-Carrasco W, Goldberg IJ, Breslow JL, Shulman GI: Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 98:7522-7527, 2001
18. Ellis BA, Poynten A, Lowy AJ, Furler SM, Chisholm DJ, Kraegen EW, Cooney GJ: Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am J Physiol 279:E554-E560, 2000
19. Houmard JA, Tanner CJ, Yu C, Cunningham PG, Pories WJ, MacDonald KG, Shulman GI: Effect of weight loss on insulin sensitivity and intramuscular long-chain fatty acyl-CoAs in morbidly obese subjects. Diabetes 51:2959-2963, 2002
20. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935, 2001
21. Civitarese AE, Jenkinson CP, Richardson D, Bajaj M, Cusi K, Kashyap S, Berria R, Belfort R, DeFronzo RA, Mandarino LJ, Ravussin E: Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of type 2 diabetes. Diabetologia 47:816-820, 2004
22. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI: Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350:664-671, 2004
23. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
24. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE: The adipocytesecreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953, 2001
25. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L: Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 108:1875-1881, 2001
26. Vaag A, Skott P, Damsbo P, Gall MA, Richter EA, Beck-Nielsen H: Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 88:1282-1290, 1991
27. Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ, Strassmann PG, Wajchenberg BL: Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48:1836-1841, 1999
28. Worm D, Henriksen JE, Vaag A, Thye-Ronn P, Melander A, Beck-Nielsen H: Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period. J Clin Endocrinol Metab 8:717-721, 1994
29. Stein DT, Balent B, Wolfe R, Telang F, Pan J, Hetherington H, Lee J, Hwang J: Intramyocellular lipid turnover is inhibited by the antilipolytic agent nicotinic acid. Diabetes 50 (Suppl. 2):A308, 2001
30. DeFronzo R, Tobin J, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 232:E214-E223, 1979
31. Simonson DC, DeFronzo RA: Indirect calorimetry: methodological and interpretative problems. Am J Physiol 258:E399-E412, 1990
32. Bligh EG, Dryer WJ: A rapid method of total lipid extraction and purification. Can J Biochem 37:911-917, 1959
33. Neschen S, Moore I, Regittnig W, Yu CL, Wang Y, Pypaert M, Petersen KF, Shulman GI: Contrasting effects of fish oil and safflower oil on hepatic peroxisomal and tissue lipid content. Am J Physiol 282:E395-E401, 2002
34. Steele R: Influence of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 82:420-430, 1959
35. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG: Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med 25322:223-228, 1990
36. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, White MF, Shulman GI: Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48:1270-1274, 1999
37. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, Slezak LA, Andersen DK, Hundal RS, Rothman DL, Petersen KF, Shulman GI: Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103:253-259, 1999
38. Kashyap SR, Belfort R, Berria R, Suraamornkul S, Pratipranawatr T, Finlayson J, Barrentine A, Bajaj M, Mandarino L, DeFronzo R, Cusi K: Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. Am J Physiol 287:E537-E546, 2004
39. Krebs M, Krssak M, Nowotny P, Weghuber D, Gruber S, Mlynarik V, Bischof M, Stingl H, Furnsinn C, Waldhausl W, Roden M: Free fatty acids inhibit the glucose-stimulated increase of intramuscular glucose-6-phosphate concentration in humans. J Clin Endocrinol Metab 86:2153-2160, 2001
40. Belfort R, Mandarino L, Kashyap S, Wirfel K, Pratipanawatr T, Berria R, DeFronzo RA, Cusi K: Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes 54:1640-1648, 2005
41. Storgaard H, Jensen CB, Bjornholm M, Song XM, Madsbad S, Zierath JR, Vaag AA: Dissociation between fat-induced in vivo insulin resistance and proximal insulin signaling in skeletal muscle in men at risk for type 2 diabetes. J Clin Endocrinol Metab 89:1301-1311, 2004
42. Kim JK, Fillmore JJ, Sunshine MJ, Albrecht B, Higashimori T, Kim DW, Liu ZX, Soos TJ, Cline GW, O'Brien WR, Littman DR, Shulman GI: PKC-theta knockout mice are protected from fat-induced insulin resistance. J Clin Invest 114:823-827, 2004
43. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GJ, Atcheson B, White MF, Kraegen EW, Shulman GI: Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 277:50230-50236, 2002
44. Itani SI, Ruderman NB, Schmieder F, Boden G: Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and Iκ-Bα. Diabetes 51:2005-2011, 2002
45. Lillioja A, Mott DM, Zawadzki JK, Young AA, Abbott WG, Bogardus C: Glucose storage is a major determinant of in vivo 'insulin resistance' in subjects with normal glucose tolerance. J Clin Endocrinol Metab 62:922-927, 1986
46. Bays H, Mandarino L, DeFronzo RA: Role of the adipocyte, FFA, and ectopic fat in the pathogenesis of type 2 diabetes mellitus. J Clin Endocrinol Metab 89:463-478, 2004
47. Stein DT, Stevenson BE, Chester MW, Basit M, Daniels MB, Turley SD, McGarry JD: The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. J Clin Invest 100:398-403, 1997
48. Hannah JS, Howard BV: Dietary fats, insulin resistance, and diabetes. J Cardiovasc Risk 1:31-37, 1994
49. Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA: Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 89:200-206, 2004
50. Bajaj M, Suraamornkul S, Kashyap S, Cusi K, Mandarino L, DeFronzo RA: Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. J Clin Endocrinol Metab 89:4649-4655, 2004
51. Fulcher GR, Walker M, Farrer M, Johnson AS, Alberti KG: Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate. Metabolism 42:308-314, 1993
52. Qvigstad E, Mostad IL, Bjerve KS, Grill VE: Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects. Am J Physiol 284:E129-E137, 2003
53. Vaag AA, Beck-Nielsen H: Effects of prolonged acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus. Acta Endocrinol (Copenh) 127:344-350, 1992